

When your patient gets a second chance at life

Choose only the Original

that gives you

The **ADVANTAGE** you need

The **ADVANTAGE** of

ADVAGRAF®
Tacrolimus prolonged release hard capsule

Available in 0.5mg, 1mg and 3mg

Indicated for prophylaxis of transplant rejection in adult kidney or liver allograft recipients*



Dear Dr. {{accFname}} {{accLname}},


• Conversion from Twice Daily to Once daily Tacrolimus = Better long term results!

Prospective study on 238 LDKT patients switched from AC-BID to TAC-OD after 12 months of transplant.

[Click Here](#)

For more information on study design and population

Clinical outcomes post-conversion to TAC-OD



Conclusion-

- 1) Conversion to Tac OD (Advagraf) from TAC BID resulted in favorable effects on blood pressure and lipid profile and post-transplant diabetes mellitus resulted in a higher percentage of patients being rejection free
- 2) Renal function was comparable before and after conversion (mean serum creatinine was 1.25 ± 0.88 vs 1.23 ± 0.78 mg/dL; $P = .9$). The incidence of

biopsy proven acute rejection was lower from 19.7% pre-conversion
versus 4.2% post-conversion

- 3) Graft and patient survival rates were comparable between the 2 tacrolimus formulations

BID: Twice daily; LDKT: Living donor kidney transplantation; OD: Once daily; TAC: Tacrolimus

1) Bakr MA, et al.. Exp Clin Transplant. 2019;17(5):594–598

2) Advagraf - India Prescribing Information 13 Mar 2024, Version 10

Sincerely,

{{userName}}

{{User.Title}}

Tel: {{User.Phone}}

Email: {{User.Email}}



Report any adverse events to Astellas Pharma India Pvt. Ltd. at pv@in.astellas.com.
Astellas Pharma India Pvt. Ltd. 301, 3rd Floor, C 7 B Square, 126 Andheri Kurla Road, Chakala, Andheri East, Mumbai 400 069, India
To unsubscribe or manage your subscription preferences, please [click here](#).
For more information about your privacy rights and how we protect your personal information, please view our [privacy notice](#)

MAT-IN-ADV-2024-00028, valid upto May 2026